🔗 Share this article

As America proceeds with sweeping changes to its vaccination schedules, an unexpected name has surfaced somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 shots throughout the global health crisis and has concentrated on alleged deaths following COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Vaccine Program

Health officials had intended to unveil sweeping revisions to the childhood vaccination calendar earlier this month, bringing the US with Denmark’s immunization schedule, sources say – a significant shift that would place the US out of alignment with a large portion of the global community with little proof for benefit. The planned update has been pushed back until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the drug and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a greater focus upon reevaluating previously authorized immunizations at the FDA.

The new acting director has often pushed for discontinuing specific childhood vaccine recommendations in the US so as to align more similar to the Danish model, a country with universal health coverage and a population roughly the population of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on immunizations – traditionally the responsibility of Dr. Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Qualifications

The appointee has no obvious experience in pharmaceutical research, regulation or administrative roles, which has been standard for former directors of the CBER. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a clinical trial. She has no expertise in leading a major agency. She is not an expert in drug approvals.”

Previous heads of CBER would “understand laws and regulations and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that former directors who headed CBER have had.”

The drug center has an vast portfolio at the FDA, Woodcock emphasized.

“The public just zeroes in on the novel medication approvals, but the generic program approves a multitude of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and other areas, and every single one need to be managed,” Woodcock noted. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial leadership aspect to the position, which manages more than 5,000 personnel. “It is a massive administrative position, if you do it right,” the former official added.

Response and Contentious Programs

Regarding inquiries about Dr. Høeg's credentials and whether this appointment indicates increased cooperation among FDA leaders on vaccines, a spokesperson responded that the “inquiries rely on flawed presumptions”.

“Her experience aligns with the duties of her role,” the representative stated, noting the period Høeg spent advising the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the commissioner’s controversial priority voucher program, a contentious one-day therapy clearance system that allegedly troubled her predecessors. “How are these drugs being chosen for this fast-track system? Who makes the decisions?” Howard said. “There is a lot of confidentiality occurring at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards more relaxed oversight of all drugs, with the exception of shots.”

Public History on Vaccines

With vaccines, Dr. Høeg has a more documented, if concerning, history, Howard said. She released a research paper using non-validated volunteer-provided data to assess the frequency of myocarditis following Covid immunization. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Among her “wish list” for the new government included revising guidelines for novel immunizations and ending “optional” vaccines, she remarked after the election on a online show. At the agency, Dr. Høeg has reportedly suggested barring young men from receiving Covid vaccinations.

“She’s an all-around ideologue who commences with her conclusions and works backwards to accommodate the science in a extremely deceptive, dishonest fashion,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow contrarians, {like|